Jingrong Jean Cui
Scientific Founder, President, CEO & DirectorDr. Jingrong Jean Cui, Ph.D, is Scientific Founder, President, CEO & Director of BlossomHill Therapeutics, Inc. since June 2020. Dr. Cui is a renowned oncology drug designer who is the lead inventor of multiple oncology medicines and clinical compounds. Dr. Cui is the scientific Founder of Turning Point Therapeutics, Inc. (Turning Point), a San Diego based biotech company focusing on turning point medicines for cancer patients. Turning Point went public on NASDAQ in April 2019 (Ticker: TPTX). In June 2022, Bristol Myers Squibb announced the acquisition of Turning Point for 4.1 billion. Dr. Cui served as Turning Point’s Chief Scientific Officer from October 2013 to January 2020 and a Member of Board of Directors from October 2013 to June 2020. Prior to that, she was Senior Principal Scientist and then Associate Research Fellow at Pfizer from 2003 to 2013. Prior to that, Dr. Cui served as Project Leader and Group Leader at SUGEN, Inc., a Pharmacia Corporation from 1999 to 2003. Dr. Cui has made significant contributions in oncology drug discovery and development. As scientific Founder of Turning Point, she focused on solving drug resistance issues in targeted therapies and invented a unique macrocyclic platform to systematically address resistance issues. This novel strategy and approach led to the creation of clinical compounds: Repotrectinib (TPX-0005), Elzovantinib (TPX-0022) and TPX-0046 within 6 years since founding the company. Repotrectinib, a ROS1/TRK/ALK inhibitor, is now in Phase 1/2 global clinical trial. Repotrectinib receive FDA Breakthrough Therapy Designations, 3 FDA Fast-Track designations and 1 FDA Orphan Drug Designation. On November 15, 2023, FDA approves Repotrectinib (AUGTYROTM) for locally advanced or metastatic ROS1+ NSCLC. Elzovantinib (TPX-0022), a MET/CSF1R/SRC inhibitor and TPX-0046, a RET/SRC inhibitor, entered into Phase 1 studies in 2019. At Pfizer, Dr. Cui was the lead inventor of Crizotinib (XALKORITM) and Lorlatinib (LORBRENATM) and worked on several other oncology projects, including SUTENTTM. Dr. Cui and her Crizotinib chemistry team at Pfizer were selected for the 38th National Inventor of the Year Award in 2011. She received Pfizer Worldwide R&D Achievement Awards (2006 and 2012) and Pfizer innovation award in 2011. Dr. Cui was an honoree for the 2013 American Chemical Society (ACS)’s Heroes of Chemistry Program for the discovery and development of Crizotinib. Dr. Cui received her 2nd Heroes of Chemistry Award from ACS in 2021 for the discovery and development of Lorlatinib. Dr. Cui received the 2022 Distinguished Alumni Achievement Award from her Ph. D. alma mater. She received 2022 San Diego BioPharma Achievement Award from SABPA in recognition of her outstanding contributions to San Diego biotech industry. Dr. Cui is the recipient of the 2023 Distinguished Scientist Award by American Chemical Society San Diego Section. She was an honoree for the Committee of Circle of Excellence Award in Humanity in Science & Technology in 2023. She was elected to the National Academy of Engineering in 2024. Dr. Cui was the winner of the inaugural CABS K. Fong Award in Life Sciences in 2013. She obtained her postdoctoral training at Lawrence Berkeley National Laboratory and the University of California Berkeley. Dr. Cui received her B.S. and M.S. in Chemistry from the University of Science and Technology of China, her Ph.D. in Organic Chemistry from The Ohio State University.
Positions
- Company NameBlossomHill Therapeutics, Inc.Stock CodeBLSMPositionScientific Founder, President, CEO & Director
